Last reviewed · How we verify

SARS-CoV-2 vaccination: Comirnaty or Vaxzevria

University of Melbourne · Phase 2 active Biologic Quality 3/100

SARS-CoV-2 vaccination: Comirnaty or Vaxzevria is a Biologic drug developed by University of Melbourne. It is currently in Phase 2 development.

At a glance

Generic nameSARS-CoV-2 vaccination: Comirnaty or Vaxzevria
SponsorUniversity of Melbourne
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about SARS-CoV-2 vaccination: Comirnaty or Vaxzevria

What is SARS-CoV-2 vaccination: Comirnaty or Vaxzevria?

SARS-CoV-2 vaccination: Comirnaty or Vaxzevria is a Biologic drug developed by University of Melbourne.

Who makes SARS-CoV-2 vaccination: Comirnaty or Vaxzevria?

SARS-CoV-2 vaccination: Comirnaty or Vaxzevria is developed by University of Melbourne (see full University of Melbourne pipeline at /company/university-of-melbourne).

What development phase is SARS-CoV-2 vaccination: Comirnaty or Vaxzevria in?

SARS-CoV-2 vaccination: Comirnaty or Vaxzevria is in Phase 2.

Related